ASBMT News  by unknown
SPECIAL-INTEREST GROUP CREATED
FOR PEDIATRIC BMT
A section for pediatric blood and
marrow transplantation has been cre-
ated within ASBMT. The new special-
interest group (SIG) was approved by
the Board of Directors in February
and a charter issued in May.
In announcing the new section,
ASBMT President Robert Negrin said,
“The purpose is to provide an interna-
tional forum for academic interaction
between health care providers with
an interest in hematopoietic cell trans-
plantation in children and adoles-
cents.” Membership is open to physi-
cians, nurses, pharmacists, ethicists,
clinical research associates, and oth-
ers who have a particular interest in
pediatric hematopoietic stem cell
transplantation.
The special-interest group will be
led by a Coordinating Committee
chaired by Morton Cowan, MD, of
the UCSF Children’s Hospital, San
Francisco. Other members of the ini-
tial committee are:
● Steven Grupp, MD, PhD—Chil-
dren’s Hospital of Philadelphia
(vice chair)
● Amanda Termuhlen, MD—Colum-
bia Children’s Hospital, Ohio
● Kirk Schultz, MD—British Columbia’s
Children’s Hospital, Vancouver
● Vicki Fisher, RN, MSN, CPNP—Uni-
versity Hospitals Health System,
Cleveland
Dr. Cowan said that the pediatric
SIG will focus first on the develop-
ment of a series of presentations at
the 2007 BMT Tandem Meetings next
February in Keystone. These will com-
plement presentations pertaining to
pediatrics in the main plenary and
concurrent scientific sessions and
workshops. Abstracts submitted on
pediatric topics will be considered for
the SIG program.
“Our objective is to promote the
exchange of information, ideas and
research advances in blood and mar-
row transplantation for diseases in
children and adolescents,” Dr.
Cowan said. “By creating a new focal
point for pediatric BMT, we think we
can increase the number of pediatric
physicians, nurses, and other health
care providers within the Society, as
well as grow the number of these
professionals attending the annual
meeting.”
When ASBMT members renew
their annual memberships, they will
have an opportunity to sign up for
membership in the SIG at no addi-
tional dues cost. Pediatric BMT is the
society’s second special interest
group. A SIG for BMT administrative
directors was formed in 1999.
H. LEE MOFFITT PHYSICIAN WINS
INVESTIGATOR AWARD
An assistant professor at the Univer-
sity of South Florida’s H. Lee Moffitt
Cancer Center & Research Institute is
the recipient of a New Investigator
Award from ASBMT and PDL Bio-
Pharma. Xue-Zhong Yu, MD, is a
member of the cancer center’s Exper-
imental Therapeutics Department. His
research concerns the function of
Tregs and T-effector cells. The
$50,000 award, payable over a two-
year term, is supported by a grant
from PDL BioPharma, Inc.
Dr. Yu will explore the molecular
mechanisms and possible clinical im-
plications of CD4CD25 T-regula-
tory cells (Tregs), a subset of T cells
that can modulate alloresponses and
possess a great potential as an immu-
notherapy in bone marrow transplan-
tation.
Dr. Yu plans a series of studies on the
function of Tregs and T-effector cells
(Teffs), with the goal of understanding
the ways in which the CD28 receptor
and inducible T-cell co-stimulator (ICOS)
control T-cell responses to alloantigen.
Both CD28 and ICOS have been found
to influence the activation and function
of Teffs as well as development and
function of Tregs.
The suppressive activity of Tregs
lacking CD28 or ICOS will be tested in
vitro and in mouse models of graft-
versus-host disease (GvHD). The ef-
fects of CD28 and ICOS on regulatory
and conventional T-cells will be exam-
ined as well. The findings will aid in
understanding the mechanisms by
which these costimulatory molecules
affect the outcomes of GvHD.
Dr. Yu said that he hopes his re-
search will contribute to new ap-
proaches to controlling donor T-cell–
induced GvHD after allogeneic bone
marrow transplantation, while pre-
serving the graft-versus-tumor effect.
NEW ICD-9-CM DIAGNOSTIC CODE
FOR ORAL MUCOSITIS
A new code for oral mucositis will
be added to the ICD-9-CM diagnostic
codes, effective Oct. 1. The Centers
for Medicare and Medicaid Services
(CMS) is adding oral mucositis in an
expansion of the “528” stomatitis
code.
“We petitioned HRSA to add a mu-
cositis code primarily for BMT pa-
tients,” said Patrick Stiff, MD, of Loyola
University Medical Center, and chair
of the ASBMT Committee on Stan-
dardization of Outcomes Reporting
and RFIs. “The new code will increase
awareness of oral mucositis toxicity,
permit us to track this toxicity in all
cancer patients, and potentially will
help in re-imbursement.”
Dr. Stiff submitted the code request
to HRSA last summer and gave a for-
mal presentation in September.
Beginning Oct. 1, the 528 diagnos-
tic codes for stomatitis and mucositis
will be:
528.00 – stomatitis and mucosi-
tis, unspecified
528.01 – mucositis (ulcerative)
due to antineoplastic therapy
528.02 – mucositis (ulcerative)
due to other drugs
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